This Government Contract opportunity from Department Of Health And Human Services was posted on July 21, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Notice of Intent to Sole Source – University of Maryland Medical Center

Closed

26-007059Federal

Submission Closed07/28/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Solicitation # 75A50126R00001_RFP_NPIVS_27

BARDA is seeking contractors to support the Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response Program. The selected providers will be responsible for furnishing all necessary personnel, materials, and facilities to produce vaccines, antigens, and adjuvants for pandemic preparedness and public health emergencies. This includes generating and submitting critical analytical, clinical, and manufacturing data to the FDA to ensure rapid regulatory decisions and manufacturing readiness. To be eligible for this award, offerors must have experience producing vaccines against influenza and strains with pandemic potential. Mandatory qualifications include either holding a U.S. influenza vaccine license or demonstrating the development of an influenza vaccine through the submission of a Biologics License Application for seasonal or pandemic vaccines. This solicitation is managed by the Department of Health and Human Services with a response deadline of October 30, 2026.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Industry Day: DARPA Documentation & Decision Support Sprint (D2)

Solicitation # DARPA-SN-26-118

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

DARPA Surgical Competition (DSC) Industry Day

Solicitation # DARPA-SN-26-125

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Human Hindbrain Organoid Functional Assay Services.

Solicitation # RFQ_CDR-2026-135968

The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.

NASA Johnson Space Center

POSTED

DEADLINE

Hypobaric Chamber Pilot Studies

Solicitation # 80JSC026Q0006

NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.

NASA Johnson Space Center

POSTED

DEADLINE

Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterThe National Institutes of Health, through the NINDS, is forecasting the establishment of a Diagnostic Research Innovation Center to support the next phase of the Undiagnosed Diseases Network. This center will operate as part of a broader ecosystem including the Clinical and Data Coordinating Center, Networks of Diagnostic Excellence, and the NIH Undiagnosed Diseases Program. The primary objective of the center is to advance innovative diagnostic tools and strategies for both genomic and non-genomic conditions, which includes the systematic re-evaluation of unsolved cases from previous network phases. The center will focus on generating and testing diagnostic hypotheses by utilizing advanced sequencing, multi-omics, and gene function studies in animal and human in vitro models. By collaborating with various network stakeholders, the center aims to identify novel disease-associated genes, genomic variants, and new syndromes. This initiative seeks an integrated center featuring investigators with a history of scientific synergy and collaboration. While this is currently a forecast to allow potential applicants time to plan and establish partnerships, formal applications are not yet being solicited.

National Institutes Of Health

POSTED

DEADLINE

study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”

Solicitation # ERP_1301373256

The Naval Medical Research Unit South in Lima, Peru, is seeking a provider to conduct a study focused on malaria and vector borne disease surveillance along the Colombia and Venezuela border. While the government has identified the Administrators of Tulane Educational Fund as the only vendor currently capable of supporting the entire requirement, they are issuing this notice to identify other capable sources before proceeding with a sole source award under FAR 13.106-1(b)(i). Interested parties must submit a capability statement including technical, management, and cost data to Genaro Vasquez via email by 12:00 PM local time on September 18, 2026. Submissions must be in Microsoft Word or PDF format, not exceed five pages, and use the subject line ERP_1301373256. The government will use these submissions to determine whether to pursue a competitive procurement or move forward with the intended sole source contract.

Naval Medical Research Center

POSTED

DEADLINE

Cryo-Electron Microscopy (Cryo-EM) Services

Solicitation # 75N98026Q01177

The National Institutes of Health Olao, under the Department of Health and Human Services, is seeking providers for Cryo-Electron Microscopy (Cryo-EM) Services under solicitation number 75N98026Q01177. This combined contract opportunity is categorized under NAICS code 541714 and is managed by the office located in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 16, 2026, at 6:00 PM. The primary point of contact for this procurement is Roxane S. Burkett.

National Institutes Of Health Olao

POSTED

DEADLINE

TIDAL: Target-Induced Droplet Assembly of Ligands

Solicitation # S-197478

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) is a programmable protein-only material that utilizes nanobodies fused with encapsulation peptides to create dynamic, liquid-like droplets through phase separation. This technology allows for the precise concentration of binders upon encountering a target ligand, enabling a versatile platform for resin-free protein purification, high-sensitivity diagnostics, and the creation of slow-release drug depots. It can also function intracellularly to sequester and neutralize harmful proteins associated with viral infections or cancer. The technology is currently at TRL 3 with a patent pending and is available for exclusive or non-exclusive licensing through the Department of Energy contractor, Triad. Key market applications span biopharmaceutical manufacturing, therapeutics, and biotechnology. Interested parties can contact Caleb Ledgerwood or Lindsay Augustyn via the provided licensing email to explore commercial partnerships for this innovation.

Triad - DOE Contractor

POSTED

DEADLINE

Master Protocol Development & Adaptive Design

POSTED

DEADLINE

Phase I/II Clinical Trial Management & Execution

W6QK Acc-Apg

POSTED

8 days ago

DEADLINE

in 5 days

AI Contract Overview

The National Institutes of Health Clinical Center plans to award a sole-source fixed-price purchase order to the University of Maryland Medical Center, LLC, to establish a biorepository of patients suspected of or diagnosed with pulmonary hypertension. The effort will involve collecting blood samples, demographic data, clinical assessments, and outcome information from enrolled subjects to support translational research aligned with all World Symposium on Pulmonary Hypertension groups. This activity is funded by the 2026 Research Award for Staff Clinicians and requires collaboration with a local center of excellence affiliated with the funding institute, justifying the non-competitive procurement under simplified acquisition procedures. The work is to be performed in Bethesda, Maryland, and the contract falls under the Product Service Code 5417 and NAICS Code 541714 for biotechnology research and development. This action is not a solicitation for quotes but a notice of intent to proceed with a sole-source award, as permitted under FAR Part 13, which allows for non-competitive contracting when only one source is reasonably available. The government has determined that competition is not required due to the specific institutional affiliation needed to maintain research integrity and compliance with the awarded funding. Interested parties may respond with their capabilities by July 28, 2026, but the government retains full discretion to proceed without competition regardless of submissions. All feedback must be directed to Kristin Nagashima at the NIH Clinical Center Office of Purchasing and Contracts via email before the deadline.

General Info

NIH to award sole-source contract to University of Maryland for pulmonary hypertension biorepository in Bethesda.

Agency

Department Of Health And Human Services → National Institutes Of Health - CcView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

MD, 20892, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJul 21

special-notice

Response DeadlineJul 28

Deadline has passed

Submission Closed

07/28/2026, 07:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health - Cc

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health - Cc

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Kristin Nagashima

contact@example.gov

Full Description

The National Institutes of Health (NIH) Clinical Center (CC) seeks a contract with University of Maryland Medical Center at Baltimore (UMB) to provide the patient population to develop a biorepository of patients suspected of or diagnosed with pulmonary hypertension (PH). The objective is to collect blood samples, demographics, clinical assessments, and outcome data in enrolled subjects. These samples will allow us to do translational research across all the World Symposium on PH groups.

• Product Service Code: 5417 – Scientific Research and Development Services

• NAICS Code: 541714 – Research and Development in Biotechnology

• Place of Performance: Bethesda, MD 20892 USA

POTS: 26-007059

Description:

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a fixed price purchase order to the University of Maryland Medical Center, LLC, located at 250 West Pratt St, 24th Floor, Baltimore, MD 21201, on a firm fixed price sole source award basis to provide the required biorepository of patients to the National Institutes of Health.

Funding for the research to be completed with the patient samples obtained through this contract is from the 2026 Research Award for Staff Clinicians (RASCL) Award to the NIH program. For the initial studies, a local PH center of excellence is required that has an institution affiliation with the IC. Thus, in order to maintain the integrity of the research plan and adhere to the proposed work that received funding, competition will be limited for this project.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by July 28, 2026 at 3pm EST.